Previous 10 | Next 10 |
home / stock / flhlf / flhlf news
TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary o...
FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN HEALTH CANADA-APPROVED PSILOCYBIN CLINICAL TRIAL Canada NewsWire Subjects were given Filament's psilocybin drug candidate in the first Canadian trial with the purpose of psychedelic therapist traini...
Filament Health press release ( OTCQB:FLHLF ): Q2 Cash and cash equivalents of C$3.0M as of June 30, 2022. For further details see: Filament Health reports Q2 results
FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY COUNCIL Canada NewsWire VANCOUVER, BC , Aug. 24, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical...
FILAMENT HEALTH ANNOUNCES EIGHTH PATENT ISSUANCE Canada NewsWire The patent describes the extraction and standardization of stable doses of psychedelic compounds and strengthens Filament's industry-leading IP portfolio VANCOUVER, BC , Aug. 17, 2022 ...
The emerging psychedelics industry is stuck with a sort of default business model that goes something like this: build a team of entrepreneurial-minded C-suite people, add a few qualified medical people, get a patented psychedelic molecule or compound to test and develop, build ...
FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , Aug. 15, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-st...
FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE Canada NewsWire The newly-launched program, led by Canadian non-profit TheraPsil, is the world's largest medical psilocybin access and data project VANCOUVER, BC , July 28, 2022 /CNW/...
Recent Progress Has Been Made In Several Areas. Filament Health has announced the dosing of the first patient in the Phase 1 trial testing orally administered psilocybin against its two formulations of psilocin. This trial will compare psilocybin with two proprietary formulations of psilocin, ...
FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT Canada NewsWire Financing led by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex VANCOUVER, BC , July 13, 2022 /CNW/ - Filament Hea...
News, Short Squeeze, Breakout and More Instantly...
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the " Acquiror "), a shareholder of Filament Health Corp. (" Filament "), announces that on June 12, 2024, it was issued 42,284,443 common shares of Filament (the " Common Shares ") from the conversion o...
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...